Shire extends ViroPharma offer while OFT deliberates
This article was originally published in Scrip
Although enough shares have already been tendered, Shire has extended its $4.2bn tender offer for the US orphan disease drug maker ViroPharma for a second time. The company told Scrip that it was waiting for clearance for the merger from the UK's Office of Fair Trading. The competition authority's decision is due on 10 February.